Description: Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Home Page: tectonictx.com
490 Arsenal Way
Watertown,
MA
02472
United States
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Alise S. Reicin M.D., Ph.D. | President, CEO, Secretary & Director |
| Dr. Marcella K. Ruddy M.D., M.S. | Chief Medical Officer |
| Mr. Daniel Lochner M.B.A. | Chief Financial Officer |
| Dr. Peter McNamara Ph.D. | Chief Scientific Officer |
| Mr. Barry Rubenstein M.S. | Senior Vice President of People & Culture |
| Mr. Anthony Muslin M.D. | Chief Development Officer |
| Dr. Marc Schwabish Ph.D. | Chief Business Officer |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5933 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-06-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |